Personalized dose selection in radiation therapy using statistical models for toxicity and efficacy with dose and biomarkers as covariates
- 27 August 2014
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 33 (30) , 5330-5339
Abstract
Selection of dose for cancer patients treated with radiation therapy (RT) must balance the increased efficacy with the increased toxicity associated with higher dose. Historically, a single dose has been selected for a population of patients (e.g., all stage III non‐small cell lung cancer). However, the availability of new biologic markers for toxicity and efficacy allows the possibility of selecting a more personalized dose. We consider the use of statistical models for toxicity and efficacy as a function of RT dose and biomarkers to select an optimal dose for an individual patient, defined as the dose that maximizes the probability of efficacy minus the sum of weighted toxicity probabilities. This function can be shown to be equal to the expected value of the utility derived from a particular family of bivariate outcome utility matrices. We show that if dose is linearly related to the probability of toxicity and efficacy, then any marker that only acts additively with dose cannot improve efficacy, without also increasing toxicity. Using a dataset of lung cancer patients treated with RT, we illustrate this approach and compare it to non‐marker‐based dose selection. Because typical metrics used in evaluating new markers (e.g., area under the ROC curve) do not directly address the ability of a marker to improve efficacy at a fixed probability of toxicity, we utilize a simulation study to assess the effects of marker‐based dose selection on toxicity and efficacy outcomes. Copyright © 2014 John Wiley & Sons, Ltd.Keywords
Funding Information
- National Institutes of Health (PO1 CA59827)
This publication has 15 references indexed in Scilit:
- Single Nucleotide Polymorphisms in DNA Repair Genes May Be Associated With Survival in Patients With Non-small Cell Lung Cancer Treated With Definitive Radiation TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Combining Physical and Biologic Parameters to Predict Radiation-Induced Lung Toxicity in Patients With Non-Small-Cell Lung Cancer Treated With Definitive Radiation TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Adaptive Randomization to Improve Utility-Based Dose-Finding with Bivariate Ordinal OutcomesJournal of Biopharmaceutical Statistics, 2012
- Quality-Adjusted Time Without Symptoms or Toxicity Analysis of Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer: An Analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 TrialJournal of Clinical Oncology, 2009
- Single Nucleotide Polymorphism at rs1982073:T869C of the TGFβ1 Gene Is Associated With the Risk of Radiation Pneumonitis in Patients With Non–Small-Cell Lung Cancer Treated With Definitive RadiotherapyJournal of Clinical Oncology, 2009
- Recent Developments in Adaptive Designs for Phase I/II Dose-Finding StudiesJournal of Biopharmaceutical Statistics, 2007
- Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma TrialJournal of the American Statistical Association, 2004
- Three-dimensional conformal radiation therapy in bronchogenic carcinomaSeminars in Radiation Oncology, 1996
- Optimization of uncomplicated control for head and neck tumorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1990
- Phase I/II study of treatment of locally advanced (T3T4) non-oat cell lung cancer with high dose radiotherapy (rapid fractionation): Radiation therapy oncology group studyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1988